Study results from I. Dichamp and colleagues update understanding of arthritis therapy
2007 NOV 19 -- Fresh data on arthritis are presented in the report 'Increased nuclear factor-kappaB activation in peripheral blood monocytes of patients with rheumatoid arthritis is mediated primarily by tumor necrosis factor-alpha.' According to a study from Besancon, France, "Rheumatoid arthritis (RA) is a disease characterized by prolonged production of tumor necrosis factor-alpha (TNF-alpha), which is regulated by the Rel/nuclear factor-kappaB (NF-kappaB) transcription factors. We assessed NF-kappaB activation in peripheral blood mononuclear cells (PBMC), peripheral blood lymphocytes (PBL), and monocytes from patients with RA, patients with ankylosing spondylitis (AS), and healthy subjects NF-kappaB activation was determined by electrophoretic mobility shift assays and by Western blotting in PBMC, monocytes, and PBL isolated from peripheral blood of patients with RA, patients with AS, and healthy subjects and determined after ex vivo pretreatment of PBMC, PBL, and monocytes of patients with RA and healthy subjects with infliximab and with etanercept Enhanced NF-kappaB activation was observed in monocytes, PBL, and PBMC isolated from patients with RA, but not in PBMC, PBL, and monocytes of patients with AS and healthy subjects." "The NF-kappaB complex was composed of p50 and p65 subunits and its activation required inhibitor of NF-kappaBalpha degradation. We observed a positive correlation between the NF-kappaB activation in monocytes, PBL, and PBMC, and TNF-alpha levels in peripheral blood of patients with RA," wrote I. Dichamp and colleagues, . The researchers concluded: "Ex vivo treatment with infliximab and etanercept decreased NF-kappaB activation in monocytes of patients with RA, but not in PBL and PBMC, and not in healthy subjects Our results indicate a role for NF-kappaB activation and TNF-alpha in the activation of monocytes of patients with RA, and suggest an important role of circulating monocytes in RA pathogenesis." Dichamp and colleagues published the results of their research in the Journal of Rheumatology (Increased nuclear factor-kappaB activation in peripheral blood monocytes of patients with rheumatoid arthritis is mediated primarily by tumor necrosis factor-alpha. Journal of Rheumatology, 2007;34(10):1976-83). For additional information, contact I. Dichamp, CHU Besancon, Dept. of Virology, Franche-Comte University, Besancon, France. The publisher of the Journal of Rheumatology can be contacted at: J Rheumatol Publ Co., 920 Yonge St., Suite 115, Toronto, Ontario M4W 3C7, Canada. Keywords: France, Besancon, Arthritis Therapy, Arthritis, Drugs, Etanercept, Necrosis, Pharmaceuticals, Rheumatoid Arthritis, Rheumatology, Therapy, Treatment. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.
|
